Trinity Capital, Inc. TRIN 深 滬
等待開盤 01-13 09:30:00 美东时间
15.95
+0.140
+0.89%
華盛通- 最 高15.98
- 今 開15.81
- 成交量 97.15万股
- 最 低 15.71
- 昨 收 15.81
- 總市值 11.22亿
- 52周最高 15.98
- 市盈率 靜 7.59
- 換手率 1.38%
- 52周最低 10.97
- 委 比 25.57%
- 總股本 7031.42万
- 歷史最高 15.98
- 量 比 0.90
- 振 幅 1.71%
- 歷史最低 3.50
- 每 手 1
- 風險率 0.85%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Trinity Capital Announces Fourth Quarter 2025 Call Details and 2026 Financial Reporting Dates
PHOENIX, Jan. 8, 2026 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the ...
01-09 05:05
Trinity Capital Announces Monthly Dividend Of $0.17/Share Each For January, February, March Of 2026
Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading international alternative asset manager, today announced that it will transition from quarterly to monthly dividends, beginning in January 2026, and the
2025-12-18 05:11
Trinity Capital declares $0.51 dividend
Trinity Capital (TRIN) declares $0.51/share quarterly dividend, in line with previous. Forward yield 13.43% Payable Jan. 15; for shareholders of record Dec. 31; ex-div Dec. 31. See TRIN Dividend Score...
2025-12-18 05:09
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
Citizens Initiates Coverage On Trinity Cap with Market Outperform Rating, Announces Price Target of $17.5
Citizens analyst Brian McKenna initiates coverage on Trinity Cap (NASDAQ:TRIN) with a Market Outperform rating and announces Price Target of $17.5.
2025-12-08 19:28
Candel pausing development of CAN-2409 in prostate cancer type
Candel Therapeutics (CADL) said it is pausing the development of CAN-2409 specifically for an indication in borderline resectable pancreatic adenocarcinoma, where it is in phase 2 testing. The company...
2025-11-15 00:47
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Candel Therapeutics reported positive results from three pivotal clinical trials for its lead product CAN-2409, including improved disease-free survival in prostate cancer patients, and plans a BLA filing in Q4 2026. The company also initiated a Phase 2 trial for metastatic NSCLC and released encouraging survival data for CAN-3110 in recurrent glioblastoma. Financially, Candel secured a $130M loan to fund its pipeline, with $87M in cash as of Sep...
2025-11-13 13:25
Trinity Cap Q3 EPS $0.52 Misses $0.53 Estimate, Sales $75.550M Beat $73.065M Estimate
Trinity Cap (NASDAQ:TRIN) reported quarterly earnings of $0.52 per share which missed the analyst consensus estimate of $0.53 by 0.95 percent. This is unchanged from the same period last year. The company reported
2025-11-05 21:03
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
2025-11-05 19:12
EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards
Trinity Capital Inc. announced a financing agreement with Bobbie, an organic infant nutrition company, to boost production capacity and ensure wider distribution of its products.
2025-10-23 19:31
